Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report) shot up 11.1% during mid-day trading on Thursday . The company traded as high as $5.00 and last traded at $5.00. 700 shares changed hands during trading, an increase of 44% from the average session volume of 485 shares. The stock had previously closed at $4.50.
Molecular Partners Price Performance
The stock’s 50 day simple moving average is $5.23 and its two-hundred day simple moving average is $5.89.
About Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
- Five stocks we like better than Molecular Partners
- How to Choose Top Rated Stocks
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- What is a Bond Market Holiday? How to Invest and Trade
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Profitably Trade Stocks at 52-Week Highs
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
